Table 2. Usual daily dose of antiparkinsonian medication (in mg/d) administered to the patients with Parkinson’s disease (PD) at the time of the examination “on” medication and individual levodopa equivalent daily doses (LEDD; in mg/d).
| Case | Medication | LEDD |
|---|---|---|
| 1 | Pramipexole 3.15a | 450 |
| 2 | L-Dopa 550, L-Dopab 300, Tolcapone 300, Pramipexole 2.45a, Amantadine 400 | 1,800 |
| 3 | L-Dopa 300, L-Dopab 100, Pramipexole 3.15a | 825 |
| 4 | L-Dopa 125, L-Dopab 500, Pramipexole 2.1a, Amantadine 600 | 1,400 |
| 5 | L-Dopa 300, Entacapone 600 | 399 |
| 6 | L-Dopa 400, L-Dopab 100, Rasagiline 1 | 575 |
| 7 | L-Dopa 1,000, Entacapone 1,000, Pramipexole 1.75a, Selegiline 10c | 1,680 |
| 8 | L-Dopa 400 | 400 |
| 9 | L-Dopa 600, Entacapone 600, Pramipexole 1.04a | 948 |
| 10 | L-Dopa 600 | 600 |
| 11 | L-Dopa 600, Rotigotine 6, Cabergoline 6, Amantadine 200 | 1,380 |
| 12 | L-Dopa 600, L-Dopab 300, Entacapone 800, Cabergoline 6 | 1,497 |
| 13 | L-Dopa 700, L-Dopab 100, Entacapone 600, Rotigotine 8 | 1,246 |
Note. aThe conversion factor for Pramipexole provided by ref. 24 refers to the salt form of Pramipexole (Pramipexole dihydrochloride 1 H2O). We used the dose of the Pramipexole salt form to calculate the LEDD, but report the corresponding dose of Pramipexole (base form) here for easier interpretation. For example, Pramipexole 3.15 (base form) corresponds to 4.5 mg Pramipexole dihydrochloride 1 H2O (salt form). bControlled-release L-Dopa dose. cOral Selegiline.